MRK:F:F-Merck & Company Inc (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 151.9

Change

+2.05 (+1.37)%

Market Cap

USD 66.78B

Volume

73.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 65.62B
ZOE:F Zoetis Inc

+2.00 (+1.31%)

USD 64.18B
TKD:F Takeda Pharmaceutical Company ..

-0.21 (-0.87%)

USD 39.41B
TKDA:F Takeda Pharmaceutical Company ..

-0.30 (-2.46%)

USD 38.72B
H6D0:F Haleon PLC

-0.04 (-1.12%)

USD 35.13B
H6D:F Haleon PLC

-0.10 (-1.36%)

USD 35.12B
TEV:F Teva Pharmaceutical Industries..

-0.10 (-0.67%)

USD 14.69B
SH0:F Shionogi & Co. Ltd

+0.40 (+0.92%)

USD 12.76B
NB3:F Neurocrine Biosciences Inc

-0.80 (-0.61%)

USD 12.70B
RDDA:F Dr. Reddy's Laboratories Limit..

-1.00 (-1.52%)

USD 11.53B

ETFs Containing MRK:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.96% 60% D- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.96% 55% F 58% F
Trailing 12 Months  
Capital Gain -6.23% 58% F 44% F
Dividend Return 1.36% 13% F 13% F
Total Return -4.88% 54% F 41% F
Trailing 5 Years  
Capital Gain 58.06% 82% B 75% C
Dividend Return 9.68% 32% F 40% F
Total Return 67.74% 67% D+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 14.12% 88% B+ 83% B
Dividend Return 15.60% 84% B 78% C+
Total Return 1.48% 50% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 27.21% 54% F 42% F
Risk Adjusted Return 57.34% 91% A- 86% B+
Market Capitalization 66.78B 100% F 97% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector